 Outlook Therapeutics NASDAQ:OTLK Inc said it has voluntarily withdrawn the biologics license application BLA for its ophthalmic formulation of bevacizumab ONS-5010 or Lytenava after the US Food and Drug Administration FDA requested additional information. The company added that it is actively working to respond to the FDAs request and plans to resubmit a revised BLA by September. 